Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.

Inclusion Criteria:

- pediatric patients aged 2-17 years of age;

- histologically confirmed solid tumors;

- cancer which has relapsed after, or failed to respond to, curative therapy, or no
other potentially curative treatment options available.

Exclusion Criteria:

- treatment with corticosteroids within past 2 weeks;

- current or past use of anti-IGF-1R antibodies;

- current treatment with immunosuppressive agents;

- patients with diabetes mellitus;

- known HIV or hepatitis B or C;

- hypersensitivity to any of the components of R1507 or to monoclonal antibodies.